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Background-—Elderly patients have high ischemic and bleeding rates after acute coronary syndrome; however, the occurrence of
these complications over time has never been studied. This study sought to characterize average daily ischemic rates (ADIRs) and
average daily bleeding rates (ADBRs) over 1 year in patients aged >74 years with acute coronary syndrome undergoing
percutaneous coronary intervention who were randomized in the Elderly ACS 2 trial, comparing low-dose prasugrel (5 mg daily)
with clopidogrel (75 mg daily).
Methods and Results-—ADIRs and ADBRs were calculated as the total number of events, including recurrent events, divided by the
number of patient-days of follow-up and assessed within different clinical phases: acute (0–3 days), subacute (4–30 days), and late
(31–365 days). Generalized estimating equations were used to test the least squares mean differences for the pairwise
comparisons of ADIRs and ADBRs and the pairwise comparison of clopidogrel versus prasugrel effects. Globally, ADIRs were 2.6
times (95% CI, 2.4–2.9) higher than ADBRs. ADIRs were signiﬁcantly higher in the clopidogrel arm than in the low-dose prasugrel
arm in the subacute phase (Padj<0.001) without a difference in ADBRs (Padj=0.35). In the late phase, ADIRs remained signiﬁcantly
higher with clopidogrel (Padj<0.001), whereas ADBRs were signiﬁcantly higher with low-dose prasugrel (Padj<0.001).
Conclusions-—Ischemic burden was greater than bleeding burden in all clinical phases of 1-year follow-up of elderly patients with
acute coronary syndrome treated with percutaneous coronary intervention. Low-dose prasugrel reduced ischemic events in the
subacute and chronic phases compared with clopidogrel, whereas bleeding burden was lower with clopidogrel in the late phase.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identiﬁer: NCT01777503. ( J Am Heart Assoc. 2019;8:
e010956. DOI: 10.1161/JAHA.118.010956.)
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A lthough elderly patients with acute coronary syndromes(ACS) represent at least a third of the overall ACS
population1,2 and are increasingly treated with percutaneous
coronary intervention (PCI),3–5 few trials are devoted to this
growing group of patients. In the recently published Elderly
ACS 2 trial, which compared the effects of low-dose prasugrel
(5 mg daily) with standard dose clopidogrel (75 mg daily) for
12 months in patients aged >74 years who had an ACS and
were undergoing PCI, no signiﬁcant difference was found
between the 2 pharmacological treatment modalities regarding
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the primary composite end point of ischemic and bleeding
events. However, bleeding rates tended to be lower with
clopidogrel, whereas the rates of stent thrombosis, cardiovas-
cular death, myocardial infarction (MI), and stroke were
numerically lower with the use of low-dose prasugrel.6
Although it is known that elderly patients have increased
rates of both ischemic and bleeding events compared with
younger patients,7,8 the occurrence of these complications
over time has never been studied. If peaks of ischemic and
bleeding events occur at different times, a more potent
antiplatelet regimen may be considered when ischemic events
prevail, whereas a less aggressive treatment could be
proposed when bleeding complications are more frequent
than ischemic complications.9,10 In this analysis, we aimed to
characterize the total temporally related burden of ischemic
and bleeding events in patients randomized in the 2 arms of
the Elderly ACS 2 trial.
Methods
Study Design and Objectives
The study design of the Elderly ACS 2 trial has been described
previously.5,11 The authors declare that all supporting data are
available within the article (and the online supplementary
ﬁles). Brieﬂy, the study was a randomized, open-label, blinded-
end-point trial carried out at 32 centers in Italy. We enrolled
patients aged >74 years with either ST-segment–elevation MI
or non–ST-segment–elevation ACS undergoing PCI during the
index admission. Patients with non–ST-segment–elevation
ACS were eligible if they had one of the following additional
characteristics: elevated troponin levels, diabetes mellitus,
prior MI, ≥1 new ischemic episode while on standard
treatment during the index hospitalization, or stent thrombo-
sis. We excluded patients with prior stroke, gastrointestinal or
genitourinary bleeding within the previous 6 weeks, hemoglo-
bin level <10 g/dL on admission unless this was considered
to be secondary to renal dysfunction or known myelodys-
plasia, platelet count <90 000 cells/mL, secondary causes of
ischemia, ongoing oral anticoagulant treatment or a sponta-
neous international normalized ratio >1.5 at the time of
screening, concomitant severe obstructive lung disease,
malignancy, or neurological deﬁcit limiting follow-up or
adherence to the study protocol. Institutional review board
approval was obtained according to the guidelines of the
Journal of the American Heart Association. The study was
approved by an institutional review committee, and patients
gave informed consent; patients who were unable to give at
least verbal informed consent to the study or were already
under treatment with prasugrel or ticagrelor were excluded.
Participants were randomly assigned to either clopidogrel
(300- to 600-mg loading dose [at investigator discretion]
followed by 75 mg once daily) or prasugrel (60-mg loading
dose followed by 5 mg once daily) with a 1:1 allocation.
Treatment assignment was stratiﬁed by center and type of
ACS (ST-segment–elevation versus non–ST-segment–eleva-
tion). Follow-up visits were to take place at 30 days,
6 months, and 12 months after randomization.
All deﬁnitions of the primary-end-point components have
been published previously.5,10 Because the study compared 2
antiplatelet agents with different P2Y12 receptor-blocking
potency, the primary end point of the study was a “net clinical
beneﬁt” composite of all-cause death, MI, disabling stroke,
and rehospitalization for cardiovascular causes or bleeding.
All events were adjudicated by an independent event adjudi-
cation committee (including 3 expert cardiologists and 1
neurologist) blinded to study group assignment.
The objectives of the present study were as follows: (1) to
determine the average daily ischemic rate (ADIR) and average
daily bleeding rate (ADBR) during the ﬁrst year following the
index event and within different clinical phases (acute,
subacute, late) and (2) to determine how the randomized
antiplatelet treatments (clopidogrel 75 mg once daily versus
prasugrel 5 mg once daily) affected ADIR and ADBR in the
various clinical phases.
End-Point and Time-Interval Deﬁnitions
Ischemic events included in the ADIR were cardiovascular
death, MI, and stroke. Events included in the ADBR were
bleeding events deﬁned according to Bleeding Academic
Clinical Perspective
What Is New?
• The analysis of recurrent events in elderly patients (aged
>74 years) undergoing percutaneous coronary intervention
for acute coronary syndrome shows that ischemic events
are 2 times higher than bleeding events in all time periods
up to 1 year of follow-up.
• Prasugrel and clopidogrel have variable impact on the
balance of ischemic versus bleeding events during the time
course of follow-up.
• Low-dose prasugrel reduced ischemic events in the suba-
cute and chronic phases compared with clopidogrel,
whereas bleeding burden was increased in the late phase.
What Are the Clinical Implications?
• This analysis may help clinicians individualize antithrombotic
treatment of elderly patients who are invasively managed
after acute coronary syndrome according to their baseline
thrombotic and bleeding risk and to their time period after
acute coronary syndrome.
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Research Consortium (BARC) types 2, 3, and 5, excluding types
1 and 4 (related to coronary artery bypass grafting).12 The
average daily rates (ADRs) for ischemic and bleeding events
were categorized according to the time of their occurrence at
the following time intervals: acute phase (0–3 days), subacute
phase (4–30 days), and late phase (31–365 days).
Statistical Analysis
Ischemic and bleeding events were examined in the intention-
to-treat Elderly ACS 2 population according to the approach
described by Giustino et al.13 By including recurrent events,
instead of just ﬁrst event, this approach will increase power to
capture subtle differences in outcome; furthermore, it allows
comparison of absolute differences in outcome rates to show
the degree of beneﬁt or harm of a given randomized treatment.
All ischemic or bleeding events per patient were considered in
the analysis, as opposed to the conventional approach of time
to ﬁrst-event survival. Ischemic events leading to a bleeding
event (or vice versa) were considered as 2 separate, discrete
events. Recurrent ischemic or bleeding events, respectively,
were considered to be related and counted as 1 discrete event if
occurring within 24 hours or if otherwise speciﬁed in medical
records. The ADR was deﬁned as the total number of events
(numerator) divided by the patient-days at risk (denominator).
Patient-days at risk were deﬁned as the number of patients
multiplied by how many days each patient was at risk in that
given period, including partial intervals of patients who died or
were lost to follow-up. A generalized estimating equation was
ﬁtted for analysis and to generate the least squares mean
differences among the acute, subacute, and late time periods,
with the patient-days at risk as a repeated measure and
assuming a Poisson distribution; type of event (ischemic versus
bleeding), randomized treatment and clinical phase (acute,
subacute, and late) were also included in the model as
covariates. This analysis compared the ADRs per patient and
was used to estimate the least squares mean difference and
95% CI for the pairwise comparisons of ischemic versus
bleeding events within each speciﬁc interval and pairwise
comparisons of clopidogrel versus prasugrel ADIR and ADBR
within each speciﬁc interval. Pairwise post hoc comparison
P values were adjusted with the Tukey correction. All statistical
tests were 2-sided. A P value <0.05 was considered statistically
signiﬁcant for hypothesis testing. Data were analyzed in R
environment 3.4.3 (R Foundation for Statistical Computing)
using the “geepack” and “lsmeans” packages.
Results
Baseline clinical characteristics of patients enrolled in the
Elderly ACS 2 study are already published and shown in
Table S1. Among the 1443 ACS patients enrolled in the
Elderly ACS 2 trial, 109 discrete ischemic events (cardiovas-
cular death, MI, and stroke) and 49 BARC types 2,3, and 5
bleeding events occurred within the ﬁrst year following PCI
(Tables 1 and 2); the rate of recurrent bleeding was 8.1%,
whereas the rate of recurrent ischemic events was 5.5%. The
proportion of ischemic and bleeding events occurring in the
acute, subacute, and late time intervals, as per randomized
treatment, are shown in Table 3. Of note, 49 of 109 (44.9%)
ischemic events, including 33 of 57 (58.9%) cardiovascular
deaths, occurred within 30 days, compared with 17 of 49
(34.7%) bleeding events.
Table 1. Events Included in the ADIR Numerator
Clopidogrel
75 mg
once daily
Prasugrel
5 mg
once daily
Events
in ADIR
Cardiovascular deaths 31 25 56
Nonfatal re-MI 17 16 33
Fatal re-MI 3 4 7
Non fatal stroke 13 7 20
Fatal stroke 1 0 1
Total event in ADIR 61 48 109
ADIR indicates average daily ischemic rate; MI, myocardial infarction.
Table 2. Events Included in ADBR Numerator
Clopidogrel
75 mg
once daily
Prasugrel
5 mg
once daily
Events
in ADBR
All bleeding events 21 29 50
CABG related* 1 0 1
Fatal 0 1 0
Recurrent events† 3 0 0
Patients with both
bleeding and
ischemic events
0 4 0
Bleeding preceding
unrelated ischemic event
0 3 0
Ischemic event
preceding unrelated
bleeding event
0 1 0‡
Total bleeding
events in ADBR
20 29 49‡
ADBR indicates average daily bleeding rate; CABG, coronary artery bypass grafting.
*Excluded by ADBR.
†Considered as 2 unrelated discrete events.
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Average Daily Ischemic and Bleeding Rates
Within 1 Year
Both ADIR and ADBR peaked in the ﬁrst day after PCI (0.97 and
0.47 events per 100 patients-days at risk, respectively) and
exponentially decreased thereafter. ADIRs andADBRsoccurring in
each clinical phase are shown in Figure 1 for comparison; globally,
ADIRs were, on average, 2.6 times (95% CI, 2.4–2.9) higher than
ADBR and were signiﬁcantly higher in each clinical phase. A
complete set of pairwise comparisons is shown in Table S2.
Average Daily Ischemic, Bleeding, and Net
Clinical Beneﬁt Rates According to the
Randomized Arms
Differences in ADR between patients receiving clopidogrel
versus prasugrel after PCI are shown in Figures 2 and 3 and in
Table 4. The ADIRs were higher in the clopidogrel arm, with a
maximum absolute rate difference occurring in the subacute
phase, whereas ADBR, almost overlapping between the study
arms until the 30th day, became progressively higher in
patients receiving prasugrel. In the acute phase, we found no
difference in ADIR and ADBR between the study arms,
whereas in the subacute phase, patients receiving clopidogrel
had a signiﬁcantly higher absolute difference of ADIR (least
squares mean difference: 0.088; 95% CI, 0.069–0.106;
Padj<0.001), and a nonsigniﬁcantly lower ADBR (least squares
mean difference: 0.014; 95% CI, 0.021–0.007; Padj=0.35)
than patients receiving low-dose prasugrel.
In the late phase, the magnitude of absolute differences
between the 2 treatments was smaller than in the subacute
phase. Although ADBRs were signiﬁcantly higher with low-
dose prasugrel than with clopidogrel, ADIRs remained signif-
icantly higher with clopidogrel than with low-dose prasugrel
(Table 4).
Discussion
The relevant data of this analysis are as follows: First,
ischemic events were more than twice as frequent as bleeding
events during the 12-month follow-up period, with this
difference being more pronounced in the acute and subacute
phases and decreasing exponentially thereafter. Second, daily
ischemic and bleeding burdens peaked in the ﬁrst 3 days
after the ACS, remained high in the ﬁrst month, and then
gradually and steadily decreased throughout the follow-up
period. However, about a half of the ischemic events occurred
within the ﬁrst 30 days (with a peak of 61% for cardiovascularTable 3. Discrete Events Within Each Clinical Phase Divided
by Randomization Treatment
Clopidogrel
75 mg once daily
Prasugrel
5 mg once daily
Events, n Events, n
Acute phase (days 0–3)
Ischemic events 9 8
Cardiovascular death 4 5
MI 2 2
Stroke 3 1
Bleeding events 3 4
Subacute phase (days 4–30)
Ischemic events 22 10
Cardiovascular death 16 8
MI 3 1
Stroke 3 1
Bleeding events 6 4
Late phase (days 31–365)
Ischemic events 29 30
Cardiovascular death 11 12
MI 12 13
Stroke 6 5
Bleeding events 11 21
MI indicates myocardial infarction.
Figure 1. Bleeding vs ischemic average event rate in the Elderly
2 ACS study patients. The 2 box plots show the distribution of
average daily rate (ADR) of ischemic (red) and bleeding (blue)
events within each clinical phase. The ADR was deﬁned as the
total number of events (numerator) divided by the patient-days at
risk (denominator). Patient-days at risk were deﬁned as number of
patients multiplied by how many days each patient was at risk in
that given period including partial intervals of patients who died or
were lost to follow-up. Green brackets show the least squares
mean difference (LSMD), that is, the absolute difference of ADR of
ischemic events vs ADR of bleeding events in the time course of
1-year follow-up. Positive LSMD indicates higher ADR for ischemic
events than ADR for bleeding.
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death), whereas only a third of the bleeding complications
occurred during the ﬁrst month, and two-thirds occurred
thereafter. Third, except for the ﬁrst 3 days of treatment,
ischemic events were signiﬁcantly lower in patients assigned
low-dose prasugrel than in those assigned clopidogrel
throughout the 1-year follow-up period, whereas bleeding
events were signiﬁcantly higher with prasugrel starting from
the ﬁrst month of treatment to the end of follow-up.
In this analysis, we used the methodology proposed by
Giustino et al13 to calculate ADRs of ischemic and bleeding
burdens. The advantage of this analysis is that it considers all
ischemic and bleeding events that occurred throughout the
follow-up period rather than censoring patients after occur-
rence of the ﬁrst event, as in conventional time-to-event
analyses (Kaplan–Meier methods and Cox proportional haz-
ards models).14,15 The evaluation of multiple events over time
allows full appreciation of the overall disease burden and the
effects of concomitant treatments.14 Our ﬁndings differ from
those presented in the analysis of patients undergoing
primary PCI in the HORIZONS-AMI (Harmonizing Outcomes
with Revascularization and Stents in Acute Myocardial
Infarction) trial.16 That study showed that bleeding risk
exceeded ischemic risk in the ﬁrst 3 days after the acute
event, whereas ischemic events outnumbered bleeding events
from the ﬁrst month to 1 year. The lower bleeding burden
observed in our patients in the early phase could be ascribed
to the lower use of glycoprotein IIb/IIIa inhibitors (globally
17% in the Elderly ACS 2 trial), whereas their use was part of
Figure 2. Average daily ischemic rates (ADIRs) for prasugrel
5 mg (light blue line) vs clopidogrel 75 mg (orange line) daily. The
lines plot the ADIR as a continuous variable in the time course of
follow-up. The main panel shows the overall follow-up time, the
upper small panels show (with ad hoc magniﬁcation) the ﬁrst 30 d
(upper left) including the acute and the subacute phases, which
are separated by a dotted vertical line, and the 31 to 365 d of
follow-up (upper right). The least squares mean difference (LSMD)
indicates, within each clinical phase, the absolute difference of
ADIRs between study arms; for example, positive LSMD indicates
more events occurring in patients receiving clopidogrel 75 than in
patients receiving prasugrel 5 mg. The higher the LSMD, the
greater the magnitude of effect.
Figure 3. Average daily bleeding rate (ADBR) for prasugrel 5 mg
(light blue line) vs clopidogrel 75 mg (orange line) daily. The lines
plot the ADBR as a continuous variable in the time course of
follow-up. The main panel shows the overall follow-up time; the
upper small panels show (with ad hoc magniﬁcation) the ﬁrst 30 d
(upper left) including the acute and the subacute phases, which
are separated by a dotted vertical line, and the 31 to 365 d of
follow-up (upper right). The least squares mean difference (LSMD)
indicates, within each clinical phase, the absolute difference of
ADBR between study arms; for example, negative LSMD indicates
more events in patients receiving prasugrel 5 mg compared with
patients receiving clopidogrel 75 mg.
Table 4. LSMD of ADIR and ADBR Between Patients
Randomized to Receive Clopidogrel 75 mg vs Prasugrel 5 mg
Once Daily for 12 Months
Absolute LSMD
(Clopidogrel–
Prasugrel)
Lower
95% CI
Upper
95% CI
Adjusted
P Value
ADIR
Acute 0.182 0.034 0.329 0.8215
Subacute 0.088 0.069 0.106 <0.0001
Late 0.016 0.014 0.017 <0.0001
ADBR
Acute 0.070 0.140 0.000 0.9195
Subacute 0.014 0.021 0.007 0.3524
Late 0.004 0.005 0.004 <0.0001
Positive values indicate higher ADRs for clopidogrel 75 mg daily compared with
prasugrel 5 mg daily; negative values indicate higher ADRs for prasugrel compared with
clopidogrel; the higher the LSMD in absolute value, the greater the magnitude of effect.
ADBR indicates average daily bleeding rate; ADIR, average daily ischemic rate; ADR,
average daily rate; LSMD, least squares mean difference.
*LSMD and SE are calculated by ﬁtting a generalized estimated equation model, with
patients as repeated measure and assuming Poisson distribution. The Tukey honest
signiﬁcant difference method was used to adjust P values for post hoc multiple
comparisons.
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the randomized protocol in the HORIZONS-AMI trial.16
Moreover, radial access was used in three-quarters of the
patients enrolled in the Elderly ACS 2 trial compared with the
prevailing femoral access, linked to a greater number of
bleeding events, used in the HORIZONS-AMI population. A low
bleeding rate was also observed in the recent SENIOR trial,17
in which the radial approach was used in 80% of cases. Finally,
elderly patients may have different time distribution of
bleeding events compared with younger ACS patients.
Effects of Prasugrel and Clopidogrel on Ischemic
and Bleeding Events
In the Elderly ACS 2 randomized trial, we found no difference
in the composite primary end point (the aggregate of all-cause
death, MI, disabling stroke, and rehospitalization for cardio-
vascular causes or bleeding within 1 year) between patients
assigned to low-dose prasugrel and those assigned to
clopidogrel. In the present analysis of the temporal-related
burden of adverse events, we found that treatment with low-
dose prasugrel signiﬁcantly reduced the ischemic burden
(including all cardiovascular deaths, MIs, and ischemic
strokes) from the fourth day to the end of follow-up compared
with treatment with clopidogrel. In the original analysis, low-
dose prasugrel reduced a composite ischemic end point
(cardiovascular death, MI, and stroke) by 21% compared with
clopidogrel, a difference that did not reach statistical
signiﬁcance.18 The discrepancy observed between the original
analysis and this one is due to the fact that ADR computation
of ischemic burden considers all ischemic complications
rather than the ﬁrst occurring event. Moreover, the time-
related analysis may permit identiﬁcation of periods of follow-
up in which one treatment could be found to be superior to
another. ADBR was found to be higher with low-dose
prasugrel than with clopidogrel from the 31st day to the
end of follow-up, whereas during the same period, ischemic
events were lower with low-dose prasugrel than with clopi-
dogrel. On the basis of these data, the clinician could
personalize dual-antiplatelet therapy after the ﬁrst month,
switching to a less potent antiplatelet regimen in patients with
high bleeding risk.19,20
In the TRITON–TIMI 38 (Therapeutic Outcomes by Opti-
mizing Platelet Inhibition With Prasugrel—Thrombolysis in
Myocardial Infarction 38) trial, comparing the 10-mg mainte-
nance dose of prasugrel versus clopidogrel in ACS patients,21
bleeding risk increased with age, particularly in patients aged
≥75 years, in whom fatal bleeding was signiﬁcantly higher
with prasugrel 10 mg. 22 In our study, fatal bleeding was an
exceptional occurrence, with only 1 case observed among
those randomized to low-dose prasugrel. In the United States,
use of prasugrel 10 mg in patients aged ≥75 years is
generally not recommended except in high-risk situations
(patients with diabetes mellitus or history of MI). In Europe,
this dosage is also generally not recommended in elderly
patients23 but may be considered after careful individual
beneﬁt–risk evaluation. In such cases, a reduced 5-mg
maintenance dose should be prescribed, although it had
never been tested in a randomized clinical trial of ACS
patients treated invasively.24 Data from the TRILOGY-ACS
(Targeted Platelet Inhibition to Clarify the Optimal Strategy to
Medically Manage Acute Coronary Syndromes) platelet func-
tion substudy of patients with non-ST-segment–elevation ACS
treated conservatively showed that prasugrel 5 mg induced a
signiﬁcantly higher level of platelet inhibition compared with
clopidogrel; however, this favorable pharmacodynamic proﬁle
did not result in clinical superiority of prasugrel versus
clopidogrel in that clinical setting.25
Study Limitations
In the present study we assessed ischemic events by using a
composite end point (including cardiovascular death, MI, and
stroke) that was not the primary net-beneﬁt end point of the
original analysis, which also included revascularizations for
cardiovascular causes or bleeding. However, the composite of
cardiovascular death, MI, and stroke was the primary efﬁcacy
end point in most trials comparing the effects on outcome of
different antiplatelet agents.19,26 The results of our analysis
should be applied with caution and only to an elderly
population with a globally low risk of bleeding events, such
as that enrolled in the Elderly ACS 2 trial.6 The Elderly ACS 2
trial was stopped prematurely after an interim analysis
showed a lower-than-expected rate of the primary outcome
and a virtually null between-group difference in the primary
outcome. Nevertheless, we found that bleeding rates were
signiﬁcantly higher with low-dose prasugrel than with clopi-
dogrel after the ﬁrst month of treatment. It is therefore
possible that in patients with a high bleeding risk, as
expressed by high values of the PRECISE-DAPT27 or
PARIS20,28 scores, a de-escalation strategy—starting with
low-dose prasugrel in the ﬁrst month to counteract the early
high ischemic risk, followed by a switch to clopidogrel
thereafter—could result in better 1-year clinical outcomes
than using a regimen of low-dose prasugrel for 12 months.
Conversely, if the ischemic risk prevails over the bleeding risk,
low-dose prasugrel could be continued after the ﬁrst month of
treatment.
In conclusion, this analysis shows that the overall ischemic
burden is greater than the bleeding burden in elderly patients
with ACS treated with PCI, particularly in the ﬁrst month after
the acute event. Low-dose prasugrel reduces the ischemic
events in the subacute and late phases compared with
clopidogrel, whereas the bleeding burden is lower using
clopidogrel in the late treatment phase. The analysis of
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temporal-related ischemic and bleeding events and thoughtful
assessment of the ischemic and bleeding risk may permit
tailoring the most appropriate treatment strategy in the
individual patient with ACS.
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Table S1. Baseline clinical characteristics. 
 Prasugrel 
(n=713) 
Clopidogrel 
(n=730) 
Age (median, IQR) 80 (77-84)                80 (77-84) 
Sex 
                 Female  294 (41%) 282 (39%) 
                     Male 419 (59%) 448 (61%) 
Bodyweight (kg) 72 (65-80) 72 (65-80) 
Body-mass index (kg/m2)  26 (24-28) 26 (24-28) 
Medical history 
     Family history of cardiovascular disease                    97 (14%) 118 (16 %) 
     Diabetes 215 (30%) 204 (28%) 
     Hypertension 554 (78%) 566 (78%) 
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     Hypercholesterolemia 332 (47%) 313 (43%) 
     Current smoker 62 (9%) 69  (9%) 
     Chronic respiratory failure 43 (6%) 44 (6%) 
     Liver disease  10 (1.4%) 14  (2%) 
eGFR* at admission (ml/min) 55 (19) 57 (21)       
Hemoglobin at admission (g/dL) 
                   males  13.8 (1.6)             13.8 (1.5) 
                   females 12.7 (1.4)             12.8 (1.5) 
Neurological disorders 20 (3%)             26 (3%) 
Malignancies 22 (3%)             24 (3%) 
Previous cardiovascular events 
        Myocardial infarction 137 (19%)             137 (19%) 
        Percutaneous coronary interventions 145 (20%)             119 (16%) 
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        Coronary artery bypass grafting 59 (8%)             69 (10%) 
       Peripheral vascular disease 59 (8%)            66 (9%) 
       Atrial fibrillation 32 (5%)            24 (3%) 
Ongoing cardiovascular medications 
   Aspirin 366 (62%) 350 (59%) 
   Clopidogrel  105 (18%)            109 (18%) 
   Betablockers  247 (42%)            247 (42%) 
   Calcium antagonists  171 (29%)            178 (30%) 
   ACE-inhibitors or ARBs  399 (56%)            391 (54%) 
   Diuretics  198 (34%) 224 (38%) 
   Nitrates 107 (18%)            104 (18%) 
   Statins 267 (45%)            262 (44%) 
Data are n (%), mean (SD), median (IQR), or n/N (%). There are no significant differences between treatment groups. ACE=angiotensin-converting enzyme. 
ARB=angiotensin-receptor antagonist. *estimated Glomerular Filtration Rate by the Cockroft-Gault formula.  
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Table S2. Pairwise comparisons. 
post-hoc pairwise comparisons ADR relative difference (ratio) LSMD [95%CI] adjusted p-value* 
acute, bleeding - sub-acute, bleeding 4.1 [2.77 to 6.07] <.0001 
acute, bleeding - late, bleeding 16.4 [11.34 to 23.74] <.0001 
acute, bleeding - acute, ischemic 0.43 [0.27 to 0.7] 0.0096 
acute, bleeding - sub-acute, ischemic 1.34 [0.91 to 1.97] 0.6825 
acute, bleeding - late, ischemic 6.76 [4.67 to 9.79] <.0001 
sub-acute, bleeding - late, bleeding 4 [3.44 to 4.65] <.0001 
sub-acute, bleeding - acute, ischemic 0.11 [0.07 to 0.15] <.0001 
sub-acute, bleeding - sub-acute, ischemic 0.33 [0.27 to 0.39] <.0001 
sub-acute, bleeding - late, ischemic 1.65 [1.41 to 1.92] <.0001 
late, bleeding - acute, ischemic 0.03 [0.02 to 0.04] <.0001 
late, bleeding - sub-acute, ischemic 0.08 [0.07 to 0.09] <.0001 
late, bleeding - late, ischemic 0.41 [0.38 to 0.44] <.0001 
acute, ischemic - sub-acute, ischemic 3.08 [2.19 to 4.33] <.0001 
acute, ischemic - late, ischemic 15.57 [11.28 to 21.47] <.0001 
sub-acute, ischemic - late, ischemic 5.05 [4.4 to 5.8] <.0001 
*P value adjustment: Tukey honest significant difference method for comparing a family of 6 estimates   
 
ADR= average daily rate; LSMD=least square mean difference; CI=confidence interval.  
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